[{"orgOrder":0,"company":"Lynch Regenerative Medicine","sponsor":"SMITH & NEPHEW INC","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Peptide","year":"2025","type":"Acquisition","leadProduct":"Becaplermin","moa":"Platelet-derived growth factor receptor","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Lynch Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Lynch Regenerative Medicine","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lynch Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Lynch Regenerative Medicine","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Lynch Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine"}]

Find Clinical Drug Pipeline Developments & Deals by Lynch Regenerative Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the acquisition, Lynch holds the exclusive rights to Regranex (becaplermin) gel and recombinant purified platelet-derived growth factor (PDGF). It is being indicated for diabetic foot ulcer.

                          Product Name : Regranex

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 31, 2025

                          Lead Product(s) : Becaplermin

                          Therapeutic Area : Podiatry

                          Highest Development Status : Approved FDF

                          Recipient : SMITH & NEPHEW INC

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 09, 2024

                          Lead Product(s) : Recombinant Human PDGF-BB

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Recipient : Alexander Hawkins

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 09, 2024

                          Lead Product(s) : Recombinant Human PDGF-BB

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Recipient : Vanderbilt University Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank